par Saglio, G;Kim, Sung-Soo 
;Issaragrisil, Surapol;le Coutre, Philipp;Etienne, Gabriel;Lobo, Clarisse;Pasquini, Ricardo;Clark, Richard E;Hochhaus, A.;Hughes, T P;Gallagher, Neil;Hoenekopp, Albert;Dong, Mei;Haque, A;Larson, RA;Kantarjian, Hagop M;ENESTnd Investigators,
Référence The New England journal of medicine, 362, 24, page (2251-2259)
Publication Publié, 2010-06
;Issaragrisil, Surapol;le Coutre, Philipp;Etienne, Gabriel;Lobo, Clarisse;Pasquini, Ricardo;Clark, Richard E;Hochhaus, A.;Hughes, T P;Gallagher, Neil;Hoenekopp, Albert;Dong, Mei;Haque, A;Larson, RA;Kantarjian, Hagop M;ENESTnd Investigators, Référence The New England journal of medicine, 362, 24, page (2251-2259)
Publication Publié, 2010-06
Article révisé par les pairs
| Résumé : | Nilotinib has been shown to be a more potent inhibitor of BCR-ABL than imatinib. We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (CML) in the chronic phase. |
